Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/EJE-07-0070
European Journal of Endocrinology, Vol 156, Issue 6, 679-686
Copyright © 2007 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gravholt, C. H.
Right arrow Articles by Vilstrup, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gravholt, C. H.
Right arrow Articles by Vilstrup, H.

CLINICAL STUDY

Quantitative liver functions in Turner syndrome with and without hormone replacement therapy

Claus Højbjerg Gravholt, Henrik Enghusen Poulsen1, Peter Ott2, Jens Sandahl Christiansen and Hendrik Vilstrup2

Medical Department M (Endocrinology and Diabetes), Aarhus Sygehus, Nørrebrogade, Aarhus University Hospital, DK-8000 Aarhus C, Denmark, 1 Department of Clinical Pharmacology Q7642, Rigshospitalet 2100, Copenhagen, Denmark and 2 Department of Hepato-Gastroenterology, Aarhus Sygehus, Aarhus University Hospital, 8000 Århus C, Danmark

(Correspondence should be addressed to C H Gravholt; Email: ch.gravholt{at}dadlnet.dk)

Background: Studies have documented elevated levels of liver enzymes in many females with Turner syndrome (TS). Histology has shown a range of changes. Treatment with female hormone replacement therapy (HRT) reduces liver enzymes.

Aim: To study quantitative liver functions in TS in detail with and without HRT.

Design: Randomized crossover study with active treatment (HRT in TS and P-pill in controls) or no treatment.

Subjects: Women with TS (n = 8, age 29.7 ± 5.6 (mean ± S.D.) years), verified by karyotype, and age-matched controls (C; n = 8, age 27.3 ± 4.9 years).

Methods: We determined liver enzymes in blood, used the galactose elimination capacity to assess hepatocyte cytosol activity, plasma clearance of indocyanine green to assess excretory function, antipyrine clearance to estimate microsomal activity, and the functional hepatic nitrogen clearance (FHNC) to assess mitochondrial-cytosolic metabolic capacity for conversion of amino-nitrogen.

Results: Liver enzymes were elevated in untreated TS and reduced by HRT. The hepatic capacities for conversion of galactose, indocyanine green, and antipyrine were normal and did not change by HRT. The FHNC was marginally reduced (untreated TS vs C: 19.4 ± 5.4 vs 25.2 ± 7.3 L/h, P = 0.1). FHNC changed slightly with HRT in TS (19.4 ± 5.4 vs 24.4 ± 10.2 L/h, P = 0.2).

Conclusions: The elevations of liver enzymes in untreated TS are readily suppressed by HRT. Quantitative liver functions in TS are comparable to controls and are not affected by HRT.




This article has been cited by other articles:


Home page
Br Med BullHome page
B. E. Hjerrild, K. H. Mortensen, and C. H. Gravholt
Turner syndrome and clinical treatment
Br. Med. Bull., June 1, 2008; 86(1): 77 - 93.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 European Society of Endocrinology.